

AZD8797 is an allosteric non-competitive modulator of the human CX₃CR1 receptor

Linda Cederblad*, Birgitta Rosengren†, Erik Ryberg† and Nils-Olov Hermansson*¹

*Reagents and Assay Development, Discovery Sciences, AstraZeneca R&D Gothenburg, Mölndal 431 83, Sweden

†CVMD Bioscience, Cardiovascular & Metabolic Diseases iMed, AstraZeneca R&D Gothenburg, Mölndal 431 83, Sweden

The chemokine receptor CX₃CR1 has been implicated as an attractive therapeutic target in several diseases, including atherosclerosis and diabetes. However, there has been a lack of non-peptide CX₃CR1 inhibitors to substantiate these findings. A selective small-molecule inhibitor of CX₃CR1, AZD8797, was recently reported and we present here an in-depth *in vitro* characterization of that molecule. In a flow adhesion assay, AZD8797 antagonized the natural ligand, fractalkine (CX₃CL1), in both human whole blood (hWB) and in a B-lymphocyte cell line with IC₅₀ values of 300 and 6 nM respectively. AZD8797 also prevented G-protein activation in a [³⁵S]GTPγS (guanosine 5'-[γ-thio]triphosphate) accumulation assay. In contrast, dynamic mass redistribution (DMR) experiments revealed a weak G_{αi}-dependent AZD8797 agonism. Additionally, AZD8797 positively modulated the CX₃CL1 response at sub-micromolar concentrations in a β-arrestin recruitment assay. In equilibrium saturation binding

experiments, AZD8797 reduced the maximal binding of [¹²⁵I]-CX₃CL1 without affecting K_d. Kinetic experiments, determining the k_{on} and k_{off} of AZD8797, demonstrated that this was not an artefact of irreversible or insurmountable binding, thus a true non-competitive mechanism. Finally we show that both AZD8797 and GTPγS increase the rate with which CX₃CL1 dissociates from CX₃CR1 in a similar manner, indicating a connection between AZD8797 and the CX₃CR1-bound G-protein. Collectively, these data show that AZD8797 is a non-competitive allosteric modulator of CX₃CL1, binding CX₃CR1 and effecting G-protein signalling and β-arrestin recruitment in a biased way.

Key words: allosteric modulator, CX₃CR1, fractalkine, G-protein, kinetic binding, radioligand binding.

INTRODUCTION

CX₃CL1, also named fractalkine, belongs to the large family of small secreted chemotactic cytokines called chemokines. Their main function is to coordinate leucocyte trafficking in homeostatic and inflammatory conditions [1]. Chemokines are divided into four sub-families based on the number and arrangement of a conserved cysteine motif (C, CC, CXC and CX₃C) where CX₃CL1 is the only known member of the CX₃C family [2]. CX₃CL1 is expressed as a membrane-bound molecule with the chemokine domain protruding from a mucin-like stalk, mediating the capture of circulating leucocytes. Additionally, CX₃CL1 is naturally cleaved, releasing the soluble chemokine domain and, as a consequence, it can act both as a capturing molecule and as a potent chemoattractant [3,4].

Unlike most chemokines, CX₃CL1 interacts with only one G-protein-coupled receptor: CX₃CR1 [4,5]. CX₃CR1 is expressed on smooth muscle cells, monocytes, natural killer cells and T-cells and mediates their migration, adhesion and proliferation [6]. Together, CX₃CL1 and CX₃CR1 play a key role in the inflammatory responses of several diseases, such as atherosclerosis, diabetes, cancer and pancreatic diseases; for further reading, see [6–8] for reviews. The CX₃CR1 receptor has consequently been investigated as a therapeutic target. In 2003 a CX₃CR1 knockout mouse displayed reduced atherosclerosis [9,10]. Using F1, a CX₃CR1 peptide antagonist, Poupel et al. [11] showed attenuation of atherosclerosis in high-fat-fed APOE (apolipoprotein E) KO mice. CX₃CR1 antagonism has also been shown to decrease CX₃CL1-induced extracellular matrix

accumulation in diabetic mice [12]. Karlstrom et al. [13] reported the synthesis of the first potent selective and orally available CX₃CR1 antagonist, 18a. This CX₃CR1 inhibitor, later named AZD8797 (Figure 1), has since been shown to have efficacy in a rat model for multiple sclerosis [14]. Karlstrom et al. [13] suggested AZD8797 to be an allosteric antagonist, thus affecting the CX₃CL1 interaction with CX₃CR1 by binding to the receptor at a different site from that of CX₃CL1. However, the mechanism of action of AZD8797 has so far not been studied in detail.

Modulation of receptor activation can occur in several different ways. An orthosteric antagonist competes for the same site as the natural agonist. Ligands binding elsewhere on the receptor are referred to as allosteric ligands. These can, both competitively and non-competitively, alter efficacy or affinity of orthosteric ligands. They can also exhibit agonist properties on their own. Furthermore, allosteric ligands can show different, even opposite, effects when looking at different signalling pathways or in different assays on the same pathway [15]. Several allosteric modulators have been found to target chemokine receptors [16–20]. This emerging class of allosteric drugs offers several advantages compared with more traditional competitive antagonists. They often exhibit a higher degree of selectivity and, due to the nature of the allosteric interaction, their effects are saturable, which may provide an increased therapeutic window.

In order to facilitate further *in vivo* and *in vitro* studies on CX₃CR1, the aim of our study was to extensively characterize the mechanism of action of AZD8797. To this end, we performed functional studies on human whole blood (hWB), B-lymphocyte cells and Chinese hamster ovary (CHO-K1) cells heterologously

Abbreviations: CHO-K1, Chinese hamster ovary; CL, confidence limits; DMR, dynamic mass redistribution; GTPγS, guanosine 5'-[γ-thio]triphosphate; hWB, human whole blood; NSB, non-specific binding; PEI, polyethyleneimine; PTX, pertussis toxin.

¹ To whom correspondence should be addressed (email Nils-Olov.Hermansson@astrazeneca.com).




Figure 1 Structure of AZD8797, a low-molecular mass ligand of CX₃CR1

expressing CX₃CR1 (CHO-hCX₃CR1). Using membranes from CHO-hCX₃CR1 cells, we comprehensively studied the binding properties of AZD8797. We found AZD8797 to be a potent, non-competitive, biased, allosteric modulator of CX₃CR1.

MATERIALS AND METHODS

Materials

Adherent CHO-K1 cells stably expressing hCX₃CR1 (ES-137-C) were purchased from PerkinElmer. The RPMI-8226 cell line (CCL-155) was purchased from A.T.C.C. The CHO-K1 CX₃CR1 β -arrestin cell line (93-0290C2) was from DiscoverX. hWB was collected from healthy volunteers drawn from AstraZeneca staff, giving informed consent to the work. The work was performed in accordance with the Declaration of Helsinki (2013) of the World Medical Association and has been approved by the relevant ethical committee. AZD8797 was synthesized as described previously [13]. AZD8797 is now owned by Acturum Södertälje. [³H]AZD8797 (50 Ci·mmol⁻¹, 52.932 μ M) was labelled in-house, [¹²⁵I]-CX₃CL1 (2200 Ci·mmol⁻¹) and [³⁵S]GTP γ S (guanosine 5'-[γ -thio]triphosphate) (1250 Ci·mmol⁻¹) were purchased from PerkinElmer, CX₃CL1 (8.5 kDa, soluble chemokine domain, unless otherwise stated, was the ligand used) was from Peptotech and recombinant full-length human CX₃CL1 (365-FR-025/CF) was from R&D Systems. Pertussis toxin (PTX), polyethyleneimine (PEI), GTP γ S, GDP and gelatin type A were purchased from Sigma–Aldrich and 3,3'-dihexyloxycarbonyl iodide (DiOC₆) was from Molecular Probes. HEPES, Roswell Park Memorial Institute 1640 (RPMI 1640) medium, Ham's F12 (Nutrient mixture F-12 Ham) medium, Dulbecco's modified eagle medium (DMEM), geneticin, phosphate-buffered saline (PBS), Hanks' balanced salt solution (HBSS) and Opti-MEM were purchased from Gibco (Life Technologies).

Cellix flow adhesion

Adhesion of a human B-lymphocyte cell line (RPMI-8226) or hWB leucocytes to full-length human CX₃CL1 were monitored using a microfluidics Cellix VenaFlux platform and Vena 8 Biochips (Cellix). Each channel on the Vena 8 chip was coated with anti-His monoclonal antibody (R&D Systems) followed by His-tagged full-length CX₃CL1 (R&D Systems) and blocked for non-specific binding (NSB) with BSA.

Cell preparations: RPMI-8226 cells were cultured in RPMI 1640 medium with GlutaMAX and 20% FBS (HyClone, Perbio). Before the experiment, cells were centrifuged at 320 *g* and resuspended to 5 \times 10⁶ cells·ml⁻¹ in RPMI 1640 with 1% FBS. hWB with heparin as anti-coagulant was collected from healthy donors and 5 μ M DiOC₆ was added. AZD8797 was diluted in a 3-fold series in DMSO starting at 3.3 or 30 μ M and pre-incubated with RPMI-8226 cells for 15 min or whole blood for 60 min. DMSO concentration held constant for all AZD8797 concentrations (0.1% for the RPMI-8226 experiments and 0.3% for the whole blood experiments). 100 nM CX₃CL1 (chemokine domain) was used as the control.

RPMI-8226 cells in RPMI 1640 + 1% FBS or whole blood were pumped through the channels at 0.5 dyn·cm⁻² and 2.25 dyn·cm⁻² respectively, for 3 min. Images for quantification were captured using a microscope. Cells adhering to channels were counted and the mean values across five images in each channel were used for calculating the concentration–response curves.

CX₃CR1 membrane preparation

Adherent CHO-K1 cells stably expressing human CX₃CR1 (CHO-hCX₃CR1) were grown in F12 medium with GlutaMAX, 10% FBS (Sigma–Aldrich) and 400 μ g·ml⁻¹ geneticin and harvested at 80% confluency. Cells were washed in PBS and lysed with an Ultra-Turrax Homogenizer in 50 mM Tris/HCl (pH 7.4) and 1 mM EDTA with CompleteTM protease inhibitor (Roche). After centrifugation at 1000 *g* for 10 min, membranes were collected by ultracentrifugation at 100000 *g* for 45 min at 4°C. The membranes were resuspended in 10 mM Tris/HCl (pH 7.4), 1 mM EDTA and 10% sucrose, divided into aliquots, frozen in liquid nitrogen and stored in -80°C. Protein concentration was determined using the BCA method (Thermo Fisher Scientific).

[³⁵S]-GTP γ S binding assay

CHO-hCX₃CR1 membranes (5 μ g per well) together with different concentrations of AZD8797 were incubated in 50 mM HEPES (pH 7.4), 100 mM NaCl, 5 mM MgCl₂, 10 μ M GDP and 0.01% gelatin in a MicroWell 96-well plate (Nunc). 0.56 μ Ci·ml⁻¹ [³⁵S]GTP γ S and EC₈₀ of CX₃CL1 were then added. The plate was incubated at 30°C for 1 h and subsequently unbound [³⁵S]GTP γ S was separated from bound by vacuum filtration to a Printed Filtermat B (PerkinElmer) using a Skatron Micro96 harvester and dried at 50°C for 1 h. The filters were soaked with a melt-on scintillator sheet (MeltiLex, PerkinElmer), sealed using a MeltiLex heat sealer and measured in a MicroBeta Trilux reader (PerkinElmer). The different AZD8797 concentrations were achieved by stepwise dilution in DMSO to achieve a final DMSO concentration of 1% in all wells after addition of assay buffer, regardless of AZD8797 concentration.

Dynamic mass redistribution assay

CHO-hCX₃CR1 cells were seeded at 12000 cells per well in DMEM with 10% FBS and RPMI-8226 cells at 8000 cells per well in RPMI 1640 medium with GlutaMAX and 20% FBS on 384-well fibronectin-coated EPIC™ biosensor plates (Corning) and cultured at 37°C for 24 h. At 18–24 h prior to compound treatment, the medium was replaced with serum-free medium with or without 100 ng·ml⁻¹ PTX. Cells were then washed with assay buffer (HBSS, 20 mM HEPES (pH 7.4) and 0.01% BSA) and allowed to equilibrate at 26°C for 1 h inside the EPIC™ plate reader. Following equilibration, a baseline scan was performed before adding AZD8797 or CX₃CL1 using a CyBi-Well vario (CyBio). Dynamic mass redistribution (DMR) was then measured during a 60 min scan. As in the [³⁵S]GTPγS binding assay, the final DMSO concentration was held constant at 1%.

β-Arrestin assay

β-Arrestin recruitment was measured using the PathHunter™ enzyme fragment complementation assay from DiscoverRx and carried out according to the manufacturer's instructions. In short, 3500 cells per well in Opti-MEM were incubated together with different concentrations of AZD8797 and CX₃CL1 in a 384-well plate. After 90 min of incubation at 37°C, detection reagent was added and incubation continued for 1 h at room temperature, before reading the plate with a Victor² luminescence plate reader (PerkinElmer). As in the [³⁵S]GTPγS binding assay, the final DMSO concentration was held constant at 1%.

Equilibrium binding studies

For competition binding assays, CHO-hCX₃CR1 membranes (9 μg per well) together with either 2 nM [³H]AZD8797 or 10 pM [¹²⁵I]-CX₃CL1 and different concentrations of competitor were incubated in 25 mM HEPES (pH 7.4), 10 mM MgCl₂, 1 mM CaCl₂ and 0.5% BSA in a Corning polystyrene flat-bottom 96-well plate. The plate was incubated for 2 h at room temperature before free radioligand was separated from bound by vacuum filtration on to a Multiscreen HTS + HiFlow FB (Millipore) filter plate (pre-soaked with 0.5% PEI for [¹²⁵I]-CX₃CL1 assays), using a Biomek FX (Beckman Coulter). The filter plate was washed in ice-cold 25 mM HEPES (pH 7.4), 5 mM MgCl₂, 1 mM CaCl₂ and 500 mM NaCl and dried at 50°C for 1 h. Scintillation cocktail, Optiphase Supermix (PerkinElmer) was added to each well and the radioactivity was measured using a MicroBeta Trilux reader (PerkinElmer).

[³H]AZD8797 saturation experiments were performed as above, with radioligand concentrations ranging from 0.5 to 50 nM in the absence or presence of up to 1 μM CX₃CL1 or 100 μM GTPγS. NSB was measured by adding 10 μM unlabelled AZD8797. For [¹²⁵I]-CX₃CL1 saturation experiments, 1–400 pM radioligand was used in the absence and presence of up to 10 μM AZD8797 or up to 1 mM GTPγS. Unlabelled CX₃CL1 at 100 nM was used to capture NSB. The DMSO concentration was held constant at 1%.

Kinetic radioligand-binding studies

Assays were performed as described under equilibrium binding studies with the additions stated below. Association experiments on [³H]AZD8797 were performed by adding 1 · K_d of radioligand in assay buffer in a 96-well plate. The reactions were started by addition of CHO-hCX₃CR1 membranes at different time

points and then incubated for between 1.5 min and 2 h at room temperature before being filtered. For the [³H]AZD8797 dissociation experiments 1 · K_d of radioligand was incubated with CHO-hCX₃CR1 membranes for 1 h at room temperature before starting the dissociation with the addition of 10 μM unlabelled AZD8797. The reactions were incubated for between 2.5 min and 3 h at room temperature before being filtered.

The association experiments on [¹²⁵I]-CX₃CL1 were performed as above but with 0.25 · K_d of radioligand, in the absence or presence of up to 100 μM AZD8797 or GTPγS. For the dissociation experiments 0.25 · K_d of [¹²⁵I]-CX₃CL1 was incubated with CHO-hCX₃CR1 membranes for 2 h at room temperature before CX₃CL1 and/or AZD8797 and/or GTPγS were added as indicated in the Results section. Incubation times ranged from 2.5 min to 4 h.

Calculations and data analysis

All analysis and calculations were performed using GraphPad Prism 6.01. Functional and competition binding data were analysed using non-linear regression and fitted to a sigmoidal dose-response with variable slope according to the following equation:

$$Y = \text{Bottom} + \frac{\text{Top} - \text{Bottom}}{1 + 10^{((\log X - \log X_{50}) \cdot \text{Hill slope})}}$$

where Y is the amount of radioligand bound (cpm) or functional effect, Top denotes maximal asymptotic binding, and Bottom denotes the minimal asymptotic binding. X_{50} is either the EC₅₀ or the IC₅₀ value, and X is the logarithm of the test compound concentration. K_i values were calculated from IC₅₀ values using the Cheng–Prusoff equation:

$$K_i = \frac{\text{IC}_{50}}{1 + ([\text{radioligand}] / K_d)}$$

where K_d is the radioligand dissociation constant. Saturation binding isotherms were analysed by non-linear regression and globally fitted to a hyperbolic one-site binding model taking into account both NSB and total binding to calculate the total receptor number (B_{max}) and radioligand dissociation constant (K_d):

$$Y = \frac{B_{\text{max}} \cdot X}{K_d + X} + \text{NSB}$$

where Y is the total binding expressed in pmol·mg⁻¹ CHO-hCX₃CR1 membranes and X is the radioligand concentration. NSB = NS · X + Background, where NS is the concentration-dependent NSB.

For the association experiments, the radioligand data were fitted to the following monophasic exponential association equation and the association rate (k_{on}) was calculated using the added amounts of radioligand (L) and dissociation rate (k_{off}) as constants. k_{off} was measured in separate dissociation experiments.

$$Y = \frac{L \cdot B_{\text{max}}}{L + (k_{\text{off}}/k_{\text{on}})} \cdot \left(1 - e^{-X \cdot (k_{\text{on}} \cdot L + k_{\text{off}})}\right)$$

The dissociation data were fitted to the monophasic exponential decay equation:

$$Y = (Y_0 - \text{NS}) \cdot e^{-k_{\text{off}} \cdot X} + \text{NS}$$




Figure 2 Effect of AZD8797 on adhesion of RPMI-8226 cells or hWB to CX₃CL1

Each data point is the mean \pm S.E.M. for three and two separate experiments respectively. The y-axis is normalized to the percentage of adhering cells and compared with untreated control cells.

where Y_0 is the binding (cpm) at time zero, X is the time and NS is the (non-specific) binding at infinite times. Half-life could then be calculated by dividing $\ln(2)$ by k_{off} . Multiple compound dissociation data were fitted to the biphasic exponential decay equation:

$$Y = Y_{01} \cdot e^{-k_{1\text{off}} \cdot X} + Y_{02} \cdot e^{-k_{2\text{off}} \cdot X} + \text{NS}$$

$Y_{01} + Y_{02} + \text{NS}$ equals Y_0 in the monophasic exponential decay equation. $k_{1\text{off}}$ is the dissociation rate constant for the first phase and $k_{2\text{off}}$ for the second phase.

All values are expressed as mean or geometric mean (logarithmic data) with 95% CL (confidence limits) unless otherwise stated.

To visualize the manner of binding of CX₃CL1 and AZD8797, a diagnostic affinity ratio plot designed to compare strictly competitive behaviour with allosteric interactions was used. The plot is that of $\log(K_{\text{dapp}} \cdot K_{\text{d}}^{-1} - 1)$ against $\log[\text{compound}]$, where K_{dapp} is the apparent K_{d} value measured for the radioligand in the presence of different concentrations of unlabelled test compound. For single site competitive interactions, the resulting linear plot has the slope of 1.0. For allosteric but competitive interactions, the slope will start at 1.0 but progressively deviate from unity, eventually reaching a limit governed by the allosteric ternary complex model co-operativity factor α [21,22].

RESULTS

Functional studies

Circulating leucocytes can adhere to endothelium via interaction between CX₃CR1 expressed on their surfaces and CX₃CL1 expressed on endothelial cells. Mimicking physiological flow, we monitored the adhesion of RPMI-8226 cells, a human B-lymphocyte cell line endogenously expressing human CX₃CR1 and hWB leucocytes to human full-length CX₃CL1. We found that AZD8797 prevented the capture of RPMI-8226 cells with an IC₅₀ of 5.8 nM (4.1–8.2 nM, 95% CL, $n = 3$) and human blood leucocytes with an IC₅₀ of 330 nM (280–380 nM, 95% CL, $n = 2$) (Figure 2). Pre-treatment of cells or blood with soluble CX₃CL1 produced the same total abolishment of cell adhesion (results not shown).

To study whether AZD8797 could also prevent signalling by CX₃CR1, a [³⁵S]GTP γ S accumulation assay was developed.




Figure 3 Effect of AZD8797 on CX₃CL1-induced [³⁵S]GTP γ S accumulation using CHO-hCX₃CR1 membranes

Each data point is the mean \pm S.E.M. for at least 25 separate experiments. The y-axis is normalized to the percentage of [³⁵S]GTP γ S accumulation induced by 2 nM CX₃CL1.

Adding increasing concentrations of AZD8797 to CHO-hCX₃CR1 membranes fully inhibited the response from 2 nM CX₃CL1 (EC₈₀) with an IC₅₀ of 340 nM (250–470 nM, 95% CL, $n > 24$) (Figure 3). No agonistic effect was seen for AZD8797 (results not shown).

To further study the functional response of CX₃CR1 to AZD8797 we used an EPICTM reader where we measured the DMR invoked by AZD8797 and CX₃CL1 treatment in both CHO-hCX₃CR1 and RPMI-8226 cells. CX₃CL1 gave an EC₅₀ value of 1.5 nM (1.2–1.9 nM, 95% CL, $n = 3$) in CHO-hCX₃CR1 cells (Figure 4A) and an EC₅₀ value of 7.3 nM (4.6–12 nM, 95% CL, $n = 3$) in RPMI-8226 cells (Figure 4B). We could not measure any antagonist response when challenging EC₈₀ of CX₃CL1 with different concentrations of AZD8797 (results not shown). In both cell lines, however, AZD8797 alone gave rise to signals weak in potency but similar in amplitude to CX₃CL1. In CHO-hCX₃CR1, AZD8797 had a low potency of above 5 μ M with a maximum effect of 79% of CX₃CL1 but no plateau ($n = 3$) (Figure 4C). RPMI-8226 cells responded stronger to AZD8797 with an EC₅₀ value of 410 nM (300–560 nM, 95% CL, $n = 3$) (Figure 4D). Both the AZD8797 and the CX₃CL1 signals were reduced by PTX treatment in both cell types (Figure 4). Additionally, untransfected CHO-K1 cells did not respond to CX₃CL1 (Figure 4A) and only weakly responded to AZD8797 (38% of AZD8797 effect in transfected cells) (Figure 4C).

Apart from direct antagonism, β -arrestin recruitment and subsequent internalization of the receptor could also prevent adhesion to CX₃CL1 and trigger downstream signalling pathways. To elucidate what effect AZD8797 has on the β -arrestin pathway, increasing concentrations of CX₃CL1 were tested alone and in the presence of different concentrations of AZD8797 (Figure 5). CX₃CL1 efficacy was increased almost 2-fold using 16 and 140 nM AZD8797, showing a positive allosteric modulation of the CX₃CL1 response. The effect only enhanced efficacy and not potency. However, at higher concentrations of AZD8797, the CX₃CL1-induced β -arrestin recruitment was almost abolished. AZD8797 alone showed no effect on β -arrestin recruitment.

Binding studies

To further characterize AZD8797, radioligand-binding studies with [³H]AZD8797 and [¹²⁵I]-CX₃CL1 were performed on CHO-hCX₃CR1 membranes. The binding of [¹²⁵I]-CX₃CL1 was specific




Figure 4 Effect of CX₃CL1 and AZD8797 on DMR with and without PTX treatment

Each data point is the mean \pm S.E.M. for three separate experiments. (A) Effect of CX₃CL1 on CHO-K1, CHO-hCX₃CR1 and PTX-treated CHO-hCX₃CR1 cells. (B) Effect of CX₃CL1 on PTX-treated and untreated RPMI-8226 cells. (C) Effect of AZD8797 on CHO-K1, CHO-hCX₃CR1 and PTX-treated CHO-hCX₃CR1 cells. (D) Effect of AZD8797 on PTX-treated and untreated RPMI-8226 cells.

and saturable, resulting in a K_d of 0.19 nM (0.14–0.24 nM, 95 % CL, $n = 4$) and a B_{max} of 1.7 pmol·mg⁻¹ (1.3–2.0 pmol·mg⁻¹, 95 % CL, $n = 4$) (Figure 6A). [³H]AZD8797 binding was also specific and saturable but with 14-fold more binding sites giving a B_{max} of 24 pmol·mg⁻¹ (20–28 nM, 95 % CL, $n = 4$) and a K_d of 12 nM (11–13 nM, 95 % CL, $n = 4$) (Figure 6B). Both [¹²⁵I]-CX₃CL1 and [³H]AZD8797 saturation data fitted well to the one-site non-linear regression model. Untransfected CHO-K1 cells did not bind [³H]AZD8797 in a saturable manner (results not shown). In the [¹²⁵I]-CX₃CL1 competition binding assay, unlabelled CX₃CL1 competed for CX₃CR1 binding with a K_i of 0.29 nM (0.20–0.42 nM, 95 % CL, $n = 4$) (Figure 7A). This fitted well with the determined K_d . In the same assay, AZD8797 was only able to displace [¹²⁵I]-CX₃CL1 with a 1000-fold lower potency giving an EC₅₀ of 310 nM (180–520 nM, 95 % CL, $n = 3$). Unlabelled CX₃CL1 could not displace or compete with [³H]AZD8797 (Figure 7B). Unlabelled AZD8797 competed with [³H]AZD8797 for CX₃CR1 binding with a K_i of 7.3 nM (5.6–9.5 nM, 95 % CL, $n = 7$), a significantly higher affinity than the potency shown for its displacement of [¹²⁵I]-CX₃CL1. One explanation for the discrepancy in binding sites would be that pre-bound G-proteins stabilize a high agonist

affinity subpopulation of CX₃CR1 receptors. To investigate this, GTP γ S was included to uncouple pre-bound G-protein–receptor complexes. In equilibrium saturation binding experiment GTP γ S had no effect on neither [³H]AZD8797 (results not shown) nor [¹²⁵I]-CX₃CL1 (Figure 6A).

To further elucidate the interaction between CX₃CL1 and AZD8797, [¹²⁵I]-CX₃CL1 saturation binding was performed in the presence of either AZD8797 or CX₃CL1. Adding increasing concentrations of AZD8797 decreased the B_{max} without any effect on K_d (Figure 8A). In contrast, unlabelled CX₃CL1 displayed a competitive behaviour with decreasing K_d and unchanging B_{max} (Figure 8B). Plotting the measured K_d values in an affinity ratio plot confirmed the competitive nature of the unlabelled CX₃CL1 towards the [¹²⁵I]-CX₃CL1. These results also clearly demonstrate that AZD8797 is not a competitive allosteric modulator of [¹²⁵I]-CX₃CL1 (Figure 8C).

The reduction in binding sites could be the result of AZD8797 displacing CX₃CL1 in a non-competitive manner or exhibiting very slow dissociation from the receptor. To investigate this, the association and dissociation rates of AZD8797 to hCX₃CR1 were determined. k_{on} was determined to be 1.4×10^7 M⁻¹ min⁻¹ (1.1–1.8·10⁷ M⁻¹ min⁻¹, 95 % CL) from the measured k_{obs} ($n = 5$)




Figure 5 Effect of AZD8797 on β -arrestin recruitment induced by increasing concentrations of CX₃CL1

Data shown are representative averages and S.E.M. of duplicates from one of three separate experiments. The y-axis is normalized to the effect of 1 μ M CX₃CL1 as 100%.

(Figure 9A) and k_{off} (Figure 9B). k_{off} was measured to 0.042 min^{-1} (0.031–0.052 min^{-1} , 95% CL, $n = 2$), which is equal to a half-life of approximately 17 min. Taken together these rate constants give a K_d of 2.9 nM, which is fairly close to the K_d of 12 nM measured in equilibrium binding experiments.

Probably the most sensitive method for verifying allosteric interactions is to scrutinize how the proposed allosteric ligand affects the kinetic properties of the orthosteric ligand [23]. Consequently, we measured the association and dissociation of ¹²⁵I-CX₃CL1 in the absence and presence of AZD8797. Increasing concentrations of AZD8797 decreased maximal binding of ¹²⁵I-CX₃CL1 in association experiments; however, no effect on k_{on} was seen (results not shown). Determining the k_{off} revealed a slow dissociation for ¹²⁵I-CX₃CL1 of 0.0065 min^{-1} (0.0024–0.011 min^{-1} , 95% CL, $n = 3$), corresponding to a dissociation half-life of approximately 2 h when challenged by a high concentration of unlabelled CX₃CL1 (Figure 10). An increase in the ¹²⁵I-CX₃CL1 dissociation rate was observed in the presence of AZD8797 in which the data were best fitted to a two-phase exponential decay model, displaying a fast first phase ($k_{1\text{off}} = 0.45 \text{ min}^{-1}$, 0.18–0.71 min^{-1} , 95% CL, $n = 3$) followed by a second slower phase ($k_{2\text{off}} = 0.0060 \text{ min}^{-1}$, 0.0014–0.011 min^{-1} , 95% CL, $n = 3$) (Figure 10).

To assess whether similar effects could be obtained by disrupting receptor–G-protein interactions, GTP γ S was included in experiments performed as above. Addition of GTP γ S had no effect on the ¹²⁵I-CX₃CL1 association rate or maximum binding (results not shown). However, when co-adding 100 μ M GTP γ S a clear increase in the dissociation rate of ¹²⁵I-CX₃CL1 was observed. Again the data were best described by a two-phase dissociation model ($k_{1\text{off}} = 0.55 \text{ min}^{-1}$, 0.33–0.77 min^{-1} , $k_{2\text{off}} = 0.0084 \text{ min}^{-1}$, 0.0049–0.012 min^{-1} , 95% CL, $n = 2$) (Figure 10). Finally, adding both 100 μ M GTP γ S and 100 μ M AZD8797 as well as 100 nM CX₃CL1 did not increase the dissociation of ¹²⁵I-CX₃CL1 further but exhibited the same biphasic pattern as when challenged by 100 nM CX₃CL1 together with either 100 μ M AZD8797 or 100 μ M GTP γ S (results not shown).

DISCUSSION

The aim of the present study was to investigate the allosteric mechanism of action of the first selective small-molecule inhibitor published for CX₃CR1.




Figure 6 Saturation binding using CHO-hCX₃CR1 membranes

(A) ¹²⁵I-CX₃CL1 saturation binding using CHO-hCX₃CR1 membranes alone and in the presence of 100 μ M GTP γ S. Each data point is the mean \pm S.E.M. for four and two separate experiments respectively. (B) [³H]AZD8797 saturation binding using CHO-hCX₃CR1 membranes. Each data point is the mean \pm S.E.M. for four separate experiments.

In a Cellix flow adhesion assay we studied the interaction between CX₃CR1 and CX₃CL1 and showed that RPMI-8226 cells, as well as human blood monocytes, adhere to CX₃CL1 in a low shear stress environment. This adherence can be totally abolished by addition of soluble CX₃CL1 or AZD8797. There are, however, a number of ways the cells can be prevented from adhering to CX₃CL1. To verify that the flow adhesion data were due to AZD8797 functionally antagonizing CX₃CL1 and thereby preventing downstream signalling of CX₃CR1, a [³⁵S]GTP γ S accumulation assay was developed. Using this assay, we observed that AZD8797 indeed prevented CX₃CL1 from activating the CX₃CR1-associated G_{ei} protein, albeit with a much lower potency compared with flow adhesion on RPMI-8226 cells. To adhere, a cell needs multiple receptor–CX₃CL1 interaction points and therefore it is not necessary to remove all CX₃CL1 interactions for the cell to lose its adherence. This means that the measured potency in the adhesion assay is more a measure of avidity than affinity and cannot be compared directly to the potency achieved in the [³⁵S]GTP γ S assay.

Using a label-free approach that should be more comparable to the [³⁵S]GTP γ S assay, AZD8797 surprisingly displayed agonist responses both in RPMI-8226 and in CHO-hCX₃CR1 cells. The difference in response between CHO-hCX₃CR1 and untransfected CHO-K1 cells plus the effect of PTX shows the involvement of CX₃CR1 and G_{ei} in the measured agonist responses, so that they cannot simply be put down to off-target effects. Comparing the effects in CHO-hCX₃CR1 cells, the concentration of AZD8797




Figure 7 Competition binding using CHO-hCX₃CR1 membranes

(A) Effect of CX₃CL1 and AZD8797 on [¹²⁵I]-CX₃CL1 binding to CHO-hCX₃CR1 membranes. Data shown are representative averages and S.E.M. of duplicates from one of four and three separate experiments respectively. (B) Effect of CX₃CL1 and AZD8797 on [³H]AZD8797 binding to CHO-hCX₃CR1 membranes. Data shown are representative averages and S.E.M. of duplicates from one of four and seven separate experiments respectively.

needed to elicit an agonist response is more than 10-fold higher than the concentration needed to block CX₃CL1 binding and functional response when measured using purified membranes. These results could indicate the activation of other PTX-sensitive pathways not detected by the [³⁵S]GTPγS assay, i.e. biased signalling. This can, for example, be achieved via βγ signalling [24]. Regardless of the explanation, these data suggest that AZD8797 is not a classic antagonist.

As the data suggest a receptor conformation upon AZD8797 binding that was not truly inactive and since internalization of the receptor also could present a way to prevent adhesion of CX₃CR1-expressing cells to CX₃CL1, we wanted to look at the effect of AZD8797 on β-arrestin recruitment. Additionally, β-arrestin recruitment could trigger downstream signalling pathways. AZD8797 showed a clear positive allosteric modulation of the CX₃CL1 response at sub-micromolar concentrations. AZD8797 enhanced CX₃CL1 efficacy, whereas the potency was unchanged. At higher concentrations of AZD8797, the effect was inhibitory. This could indicate that AZD8797 binds allosterically, inducing a conformational change to the receptor that potentiates β-arrestin binding and a potentially functional response while blocking fractalkine binding, albeit with a lower efficiency.




Figure 8 Effect of AZD8797 and CX₃CL1 on [¹²⁵I]-CX₃CL1 saturation binding to CHO-hCX₃CR1 membranes

(A) Specific binding of increasing concentrations of [¹²⁵I]-CX₃CL1 in the presence of different concentrations of AZD8797. Each data point is the mean ± S.E.M. for two separate experiments. (B) Specific binding of increasing concentrations of [¹²⁵I]-CX₃CL1 in the presence of different concentrations of CX₃CL1. Data shown are representative averages and S.E.M. of duplicates from one of two separate experiments. (C) An affinity ratio plot of all [¹²⁵I]-CX₃CL1 K_d values obtained in the presence of either CX₃CL1 or AZD8797. Data for both CX₃CL1 and AZD8797 were collected on two separate occasions. CX₃CL1 linear fit slope 0.73 (0.52–0.93, 95% CL, n = 2).

To separate the effects of AZD8797 on CX₃CL1 efficacy from its effects on CX₃CL1 affinity, we used radioligand-binding experiments. AZD8797 displaced [¹²⁵I]-CX₃CL1 with similar potency as measured in the [³⁵S]GTPγS assay. Allosteric modulation is often reciprocal, i.e. if AZD8797 reduces the binding of CX₃CL1, the opposite would also occur. However, CX₃CL1 was unable to compete out [³H]AZD8797 binding. This could indicate that the interaction between AZD8797 and CX₃CL1 is non-competitive, either by AZD8797 being insurmountable due to slow dissociation or by AZD8797 removing binding sites for CX₃CL1. An interesting finding is that AZD8797 is more than one order of magnitude less potent in




Figure 9 [³H]-AZD8797 kinetic binding using CHO-hCX₃CR1 membranes

(A) Association of 12 nM [³H]AZD8797 to CHO-hCX₃CR1 membranes. Each data point is the mean \pm S.E.M. for five separate experiments. (B) Dissociation of 10 nM [³H]AZD8797 from CHO-hCX₃CR1 membranes. Each data point is the mean \pm S.E.M. for two separate experiments.

displacing ¹²⁵I-CX₃CL1 than its affinity for the CX₃CR1 receptor would indicate. Maybe the two most likely explanations for this behaviour are that the ¹²⁵I-CX₃CL1 and the [³H]AZD8797 are assessing different receptor populations or that more than one AZD8797 molecule is needed to displace CX₃CL1. We also observed that ¹²⁵I-CX₃CL1 labelled only 7% of the total amount of receptors labelled by [³H]AZD8797, further indicating one or the other of the above explanations. However, both Scatchard plots and non-linear comparisons of AZD8797-binding data suggest a one-site model. Finding B_{\max} differences is not uncommon when comparing agonists with antagonists, where the agonists may only bind to the high-affinity G-protein-bound active conformation, while antagonists bind both the inactive low-affinity and the active high-affinity forms [25,26]. Looking at the influence of guanosine nucleotides in equilibrium binding showed no evidence of a high-affinity form, but, as discussed below, kinetic binding experiments clearly demonstrated its presence.

Next we wanted to verify that AZD8797 works through a non-competitive mechanism. A non-competitive ligand cannot be displaced by increasing concentrations of agonist, i.e. the agonist B_{\max} should decrease but the agonist K_d should remain unchanged. Our results confirmed this mechanism of action for AZD8797. As previously discussed, a non-competitive behaviour could be due to a very low compound off rate. We assessed the kinetics of both CX₃CL1 and AZD8797 and found both to




Figure 10 Dissociation of 0.05 nM ¹²⁵I-CX₃CL1 from CHO-hCX₃CR1 membranes

100 nM CX₃CL1 was used to prevent rebinding either alone ($n=3$) or in the presence of 10 μ M AZD8797 ($n=3$) or 100 μ M GTP γ S ($n=2$). Each data point is the mean \pm S.E.M. for the indicated number of separate experiments.

be reversible and surmountable. Therefore, since AZD8797 is able to bind to CX₃CR1 and non-competitively displace CX₃CL1, we can surmise that the receptor must be able to simultaneously bind both CX₃CL1 and AZD8797. The binding of AZD8797, however, decreases the CX₃CR1 affinity for CX₃CL1, which therefore should then dissociate from the receptor. Our results demonstrate that AZD8797 indeed profoundly increases the CX₃CL1 dissociation rate. We could also conclude that a similar effect can be achieved by adding GTP γ S, thus removing the G-protein-bound high-affinity receptor forms. Furthermore, no additive effect was seen from GTP γ S when co-adding with AZD8797, supporting a mechanism of action for AZD8797 involving G-protein displacement.

Based on the data we have presented we hypothesize that AZD8797 displaces CX₃CL1 by interfering with the interaction between CX₃CR1 and the G-protein. The hard to explain G α_i -dependent agonism seen by DMR could be an effect or an artefact of removing the G-protein from CX₃CR1. Furthermore, the lowered potency in displacing CX₃CL1 compared with AZD8797's own affinity fits well with AZD8797 having a higher affinity for the uncoupled CX₃CR1 than for the G-protein-bound receptor. Karlstrom et al. [13] reported an almost 100-fold higher affinity of AZD8797 ($K_i = 4$ nM) in a ¹²⁵I-CX₃CL1 competition assay using human embryonic kidney (HEK293) cells co-transfected with G α_{i5} -protein. This could indicate that the G-protein composition is important for the binding of AZD8797. AZD8797 showed a positive allosteric effect in the β -arrestin assay at concentrations comparable to the binding affinity of [³H]-AZD8797. However, the antagonist action in the same assay were in the similar range as AZD8797's ability to displace ¹²⁵I-CX₃CL1. Studies on the closely related CXCR2 receptor has shown an allosteric mechanism of action of a compound, SB265610, binding intracellularly, close to the site of G-protein coupling and β -arrestin binding [16,27]. Similar binding sites have also been reported for allosteric compounds binding CCR4 and CCR5 [28]. AZD8797 was developed from and is similar to a series of CXCR2 antagonists, with a known intracellular binding site on CXCR2 [29]. The similarities between compounds and receptors together with our data led us to the hypothesis that AZD8797 also binds intracellularly near the C-terminus of CX₃CR1. Further work using mutagenesis approaches will be required to locate the

precise site of interaction between AZD8797 and the CX₃CR1 receptor.

In conclusion, we have demonstrated that AZD8797 is able to non-competitively displace and block CX₃CL1 from binding CX₃CR1 through an allosteric binding mechanism of action. We have also shown that AZD8797 effects G-protein signalling and β -arrestin recruitment in a biased way.

AUTHOR CONTRIBUTION

Linda Cederblad and Nils-Olov Hermansson designed the research study. Linda Cederblad, Nils-Olov Hermansson, Birgitta Rosengren and Erik Ryberg planned and performed the research. Linda Cederblad, Nils-Olov Hermansson, Birgitta Rosengren and Erik Ryberg analysed the data and wrote the paper.

ACKNOWLEDGEMENTS

We thank Acturum for AZD8797, Marie Castaldo for membrane preparation, Birgitta Svalstedt for β -arrestin assay work, and Tomas Drmota, Paul Wan, Niklas Larsson, Elke Ericson, Tyrell Norris and Göran Dahl for scientific discussions.

REFERENCES

- Charo, I.F. and Ransohoff, R.M. (2006) The many roles of chemokines and chemokine receptors in inflammation. *N. Engl. J. Med.* **354**, 610–621 [CrossRef PubMed](#)
- Nomenclature, IUIS/WHO Subcommittee on Chemokine (2003) Chemokine/chemokine receptor nomenclature. *Cytokine* **21**, 48–49 [CrossRef PubMed](#)
- Bazan, J.F., Bacon, K.B., Hardiman, G., Wang, W., Soo, K., Rossi, D., Greaves, D.R., Zlotnik, A. and Schall, T.J. (1997) A new class of membrane-bound chemokine with a CX₃C motif. *Nature* **385**, 640–644 [CrossRef PubMed](#)
- Haskell, C.A., Cleary, M.D. and Charo, I.F. (2000) Unique role of the chemokine domain of fractalkine in cell capture kinetics of receptor dissociation correlate with cell adhesion. *J. Biol. Chem.* **275**, 34183–34189 [CrossRef PubMed](#)
- Imai, T., Hieshima, K., Haskell, C., Baba, M., Nagira, M., Nishimura, M., Kakizaki, M., Takagi, S., Nomiya, H., Schall, T.J. and Yoshie, O. (1997) Identification and molecular characterization of fractalkine receptor CX₃CR1, which mediates both leukocyte migration and adhesion. *Cell* **91**, 521–530 [CrossRef PubMed](#)
- White, G.E. and Greaves, D.R. (2012) Fractalkine: a survivor's guide: chemokines as antiapoptotic mediators. *Arterioscler. Thromb. Vasc. Biol.* **32**, 589–594 [CrossRef PubMed](#)
- Apostolakis, S. and Spandidos, D. (2013) Chemokines and atherosclerosis: focus on the CX₃CL1/CX₃CR1 pathway. *Acta Pharmacol. Sin.* **34**, 1251–1256 [CrossRef PubMed](#)
- D'Haese, J.G., Friess, H. and Ceyhan, G.O. (2012) Therapeutic potential of the chemokine-receptor duo fractalkine/CX₃CR1: an update. *Expert Opin. Ther. Targets* **16**, 613–618 [CrossRef PubMed](#)
- Combadiere, C., Pothreau, S., Gao, J.L., Esposito, B., Casanova, S., Lee, E.J., Debre, P., Tedgui, A., Murphy, P.M. and Mallat, Z. (2003) Decreased atherosclerotic lesion formation in CX₃CR1/apolipoprotein E double knockout mice. *Circulation* **107**, 1009–1016 [CrossRef PubMed](#)
- Lesnik, P., Haskell, C.A. and Charo, I.F. (2003) Decreased atherosclerosis in CX₃CR1^{-/-} mice reveals a role for fractalkine in atherogenesis. *J. Clin. Invest.* **111**, 333–340 [CrossRef PubMed](#)
- Poupel, L., Boissonnas, A., Hermand, P., Dorgham, K., Guyon, E., Auvynet, C., Charles, F.S., Lesnik, P., Deterre, P. and Combadiere, C. (2013) Pharmacological inhibition of the chemokine receptor, CX₃CR1, reduces atherosclerosis in mice. *Arterioscler. Thromb. Vasc. Biol.* **33**, 2297–2305 [CrossRef PubMed](#)
- Song, K.H., Park, J., Park, J.H., Natarajan, R. and Ha, H. (2013) Fractalkine and its receptor mediate extracellular matrix accumulation in diabetic nephropathy in mice. *Diabetologia* **56**, 1661–1669 [CrossRef PubMed](#)
- Karlstrom, S., Nordvall, G., Sohn, D., Hettman, A., Turek, D., Ahlin, K., Kers, A., Claesson, M., Slivo, C., Lo-Alfredsson, Y. et al. (2013) Substituted 7-amino-5-thio-thiazolo[4,5-d]pyrimidines as potent and selective antagonists of the fractalkine receptor (CX₃CR1). *J. Med. Chem.* **56**, 3177–3190 [CrossRef PubMed](#)
- Ridderstad Wollberg, A., Ericsson-Dahlstrand, A., Jureus, A., Ekerot, P., Simon, S., Nilsson, M., Wiklund, S.J., Berg, A.L., Ferm, M., Sunnemark, D. and Johansson, R. (2014) Pharmacological inhibition of the chemokine receptor CX₃CR1 attenuates disease in a chronic-relapsing rat model for multiple sclerosis. *Proc. Natl. Acad. Sci. U.S.A.* **111**, 5409–5414 [CrossRef PubMed](#)
- Gregory, K.J., Valiant, C., Simms, J., Sexton, P.M. and Christopoulos, A. (2010) The emergence of allosteric modulators for G protein-coupled receptors. In *GPCR Molecular Pharmacology and Drug Targeting: Shifting Paradigms and New Directions* (Gilchrist, A., ed.), pp. 61–68, Wiley, Hoboken [CrossRef](#)
- Bradley, M.E., Bond, M.E., Manini, J., Brown, Z. and Charlton, S.J. (2009) SB265610 is an allosteric, inverse agonist at the human CXCR2 receptor. *Br. J. Pharmacol.* **158**, 328–338 [CrossRef PubMed](#)
- Bertini, R., Allegritti, M., Bizzarri, C., Moriconi, A., Locati, M., Zampella, G., Cervellera, M.N., Di Cioccio, V., Cesta, M.C., Galliera, E. et al. (2004) Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. *Proc. Natl. Acad. Sci. U.S.A.* **101**, 11791–11796 [CrossRef PubMed](#)
- Sabroe, I., Peck, M.J., Van Keulen, B.J., Jorritsma, A., Simmons, G., Clapham, P.R., Williams, T.J. and Pease, J.E. (2000) A small molecule antagonist of chemokine receptors CCR1 and CCR3. potent inhibition of eosinophil function and CCR3-mediated HIV-1 entry. *J. Biol. Chem.* **275**, 25985–25992 [CrossRef PubMed](#)
- Sachpatzidis, A., Benton, B.K., Manfredi, J.P., Wang, H., Hamilton, A., Dohlman, H.G. and Lolis, E. (2003) Identification of allosteric peptide agonists of CXCR4. *J. Biol. Chem.* **278**, 896–907 [CrossRef PubMed](#)
- Dorr, P., Westby, M., Dobbs, S., Griffin, P., Irvine, B., Macartney, M., Mori, J., Rickett, G., Smith-Burchnell, C., Napier, C. et al. (2005) Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. *Antimicrob. Agents Chemother.* **49**, 4721–4732 [CrossRef PubMed](#)
- Cheng, Y. and Prusoff, W.H. (1973) Relationship between the inhibition constant (K₁) and the concentration of inhibitor which causes 50 per cent inhibition (I₅₀) of an enzymatic reaction. *Biochem. Pharmacol.* **22**, 3099–3108 [CrossRef PubMed](#)
- Hulme, E.C. and Trevethick, M.A. (2010) Ligand binding assays at equilibrium: validation and interpretation. *Br. J. Pharmacol.* **161**, 1219–1237 [CrossRef PubMed](#)
- Christopoulos, A. and Kenakin, T. (2002) G protein-coupled receptor allosterism and complexing. *Pharmacol. Rev.* **54**, 323–374 [CrossRef PubMed](#)
- Steen, A., Larsen, O., Thiele, S. and Rosenkilde, M.M. (2014) Biased and g protein-independent signaling of chemokine receptors. *Front. Immunol.* **5**, 277 [CrossRef PubMed](#)
- Mazzoni, M.R., Martini, C. and Lucacchini, A. (1993) Regulation of agonist binding to A_{2A} adenosine receptors: effects of guanine nucleotides (GDP[S] and GTP[S]) and Mg²⁺ ion. *Biochim. Biophys. Acta* **1220**, 76–84 [CrossRef PubMed](#)
- Keen, M. (1997) Radioligand-binding methods for membrane preparations and intact cells. *Methods Mol. Biol.* **83**, 1–24 [PubMed](#)
- Salchow, K., Bond, M.E., Evans, S.C., Press, N.J., Charlton, S.J., Hunt, P.A. and Bradley, M.E. (2010) A common intracellular allosteric binding site for antagonists of the CXCR2 receptor. *Br. J. Pharmacol.* **159**, 1429–1439 [CrossRef PubMed](#)
- Andrews, G., Jones, C. and Wreggett, K.A. (2008) An intracellular allosteric site for a specific class of antagonists of the CC chemokine G protein-coupled receptors CCR4 and CCR5. *Mol. Pharmacol.* **73**, 855–867 [CrossRef PubMed](#)
- Nicholls, D.J., Tomkinson, N.P., Wiley, K.E., Brammall, A., Bowers, L., Grahames, C., Gaw, A., Meghani, P., Shelton, P., Wright, T.J. and Mallinder, P.R. (2008) Identification of a putative intracellular allosteric antagonist binding-site in the CX₃C chemokine receptors 1 and 2. *Mol. Pharmacol.* **74**, 1193–1202 [CrossRef PubMed](#)

Received 30 April 2015/9 December 2015; accepted 11 December 2015
Accepted Manuscript online 11 December 2015, doi:10.1042/BJ20150520